INNOVATIVE METHOD FOR RAPID AND LOW-COST SARS-COV-2 RESEARCH IN RESPIRATORY SAMPLES: VALIDATION WITH MULTIPLE DIAGNOSTICS AND PROCESS AUTOMATION (Q4201970): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Changed label, description and/or aliases in en, and other parts: Adding English translations) |
||||||||||||||
| label / en | label / en | ||||||||||||||
INNOVATIVE METHOD FOR RAPID AND LOW-COST SARS-COV-2 RESEARCH IN RESPIRATORY SAMPLES: VALIDATION WITH MULTIPLE DIAGNOSTICS AND PROCESS AUTOMATION | |||||||||||||||
| Property / summary | |||||||||||||||
THE PHASE 2 CONSORTIUM CONSISTS OF RESEARCH BODIES AND INDUSTRIAL PARTNERS, CHARACTERISED BY ONGOING COLLABORATIONS AND ESTABLISHED SECTOR-SPECIFIC EXPERTISE, ABLE TO ENSURE THE ACHIEVEMENT OF THE OBJECTIVES ON TIME. THE PARTNERSHIP CONSISTS OF 2 UNIVERSITIES (UNIVERSITÃ DI MILANO (UNIMI) AND UNIVERSITY OF MILAN-BICOCCA (UNIMIB)), 2 ASST (ASST MONZA, ASST PAPA GIOVANNI XXIII BERGAMO), 2 LARGE ENTERPRISES (COPAN, LUTECH) AND A SMALL ENTERPRISE (HIANTIS). INTEGRATED EXPERTISE ENSURES THE CLINICAL DEVELOPMENT AND VALIDATION POTENTIAL OF MEDICAL DEVICES (IVDS) AND DIAGNOSTIC PROCESSES, WHICH CAN BE QUICKLY IMPLEMENTED IN CLINICAL PRACTICE. PROJECT OBJECTIVES:Â DEVELOPMENT AND OPTIMISATION OF A NEW PRE-ANALYTICAL METHOD/PROCESS (APRIL-JUNE 2020), FOR THE EXTRACTION OF VIRAL RNA DIRECTLY FROM THE NASOPHARYNGEAL BUFFER, MAKING THE TEST QUICK, SIMPLE, SAFE (VIRAL INACTIVATION) AND EXECUTABLE ALSO ON DRY-CARRIED SWABS (ENTITIES INVOLVED: (English) | |||||||||||||||
| Property / summary: THE PHASE 2 CONSORTIUM CONSISTS OF RESEARCH BODIES AND INDUSTRIAL PARTNERS, CHARACTERISED BY ONGOING COLLABORATIONS AND ESTABLISHED SECTOR-SPECIFIC EXPERTISE, ABLE TO ENSURE THE ACHIEVEMENT OF THE OBJECTIVES ON TIME. THE PARTNERSHIP CONSISTS OF 2 UNIVERSITIES (UNIVERSITÃ DI MILANO (UNIMI) AND UNIVERSITY OF MILAN-BICOCCA (UNIMIB)), 2 ASST (ASST MONZA, ASST PAPA GIOVANNI XXIII BERGAMO), 2 LARGE ENTERPRISES (COPAN, LUTECH) AND A SMALL ENTERPRISE (HIANTIS). INTEGRATED EXPERTISE ENSURES THE CLINICAL DEVELOPMENT AND VALIDATION POTENTIAL OF MEDICAL DEVICES (IVDS) AND DIAGNOSTIC PROCESSES, WHICH CAN BE QUICKLY IMPLEMENTED IN CLINICAL PRACTICE. PROJECT OBJECTIVES:Â DEVELOPMENT AND OPTIMISATION OF A NEW PRE-ANALYTICAL METHOD/PROCESS (APRIL-JUNE 2020), FOR THE EXTRACTION OF VIRAL RNA DIRECTLY FROM THE NASOPHARYNGEAL BUFFER, MAKING THE TEST QUICK, SIMPLE, SAFE (VIRAL INACTIVATION) AND EXECUTABLE ALSO ON DRY-CARRIED SWABS (ENTITIES INVOLVED: (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: THE PHASE 2 CONSORTIUM CONSISTS OF RESEARCH BODIES AND INDUSTRIAL PARTNERS, CHARACTERISED BY ONGOING COLLABORATIONS AND ESTABLISHED SECTOR-SPECIFIC EXPERTISE, ABLE TO ENSURE THE ACHIEVEMENT OF THE OBJECTIVES ON TIME. THE PARTNERSHIP CONSISTS OF 2 UNIVERSITIES (UNIVERSITÃ DI MILANO (UNIMI) AND UNIVERSITY OF MILAN-BICOCCA (UNIMIB)), 2 ASST (ASST MONZA, ASST PAPA GIOVANNI XXIII BERGAMO), 2 LARGE ENTERPRISES (COPAN, LUTECH) AND A SMALL ENTERPRISE (HIANTIS). INTEGRATED EXPERTISE ENSURES THE CLINICAL DEVELOPMENT AND VALIDATION POTENTIAL OF MEDICAL DEVICES (IVDS) AND DIAGNOSTIC PROCESSES, WHICH CAN BE QUICKLY IMPLEMENTED IN CLINICAL PRACTICE. PROJECT OBJECTIVES:Â DEVELOPMENT AND OPTIMISATION OF A NEW PRE-ANALYTICAL METHOD/PROCESS (APRIL-JUNE 2020), FOR THE EXTRACTION OF VIRAL RNA DIRECTLY FROM THE NASOPHARYNGEAL BUFFER, MAKING THE TEST QUICK, SIMPLE, SAFE (VIRAL INACTIVATION) AND EXECUTABLE ALSO ON DRY-CARRIED SWABS (ENTITIES INVOLVED: (English) / qualifier | |||||||||||||||
point in time: 1 February 2022
| |||||||||||||||
Revision as of 06:31, 1 February 2022
Project Q4201970 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | INNOVATIVE METHOD FOR RAPID AND LOW-COST SARS-COV-2 RESEARCH IN RESPIRATORY SAMPLES: VALIDATION WITH MULTIPLE DIAGNOSTICS AND PROCESS AUTOMATION |
Project Q4201970 in Italy |
Statements
162,637.29 Euro
0 references
325,274.58 Euro
0 references
50.0 percent
0 references
HIANTIS S.R.L.
0 references
LUTECH S.P.A.
0 references
COPAN ITALIA S.P.A.
0 references
UNIVERSITÃ DEGLI STUDI DI MILANO - BICOCCA
0 references
AZIENDA SOCIO SANITARIA TERRITORIALE PAPA GIOVANNI XXIII
0 references
AZIENDA SOCIO SANITARIA TERRITORIALE - ASST DI MONZA
0 references
IL CONSORZIO FASE 2 Ê COSTITUITO DA ENTI DI RICERCA E PARTNER INDUSTRIALI, CARATTERIZZATI DA COLLABORAZIONI IN ATTO E DA CONSOLIDATE COMPETENZE SPECIFICHE DI SETTORE, IN GRADO DI ASSICURARE IL RAGGIUNGIMENTO DEGLI OBIETTIVI NEI TEMPI PREVISTI. IL PARTENARIATO SI COMPONE DI 2 UNIVERSITà (UNIVERSITà DI MILANO (UNIMI) ED UNIVERSITà DI MILANO-BICOCCA (UNIMIB)), 2 ASST (ASST MONZA, ASST PAPA GIOVANNI XXIII BERGAMO), 2 GRANDI IMPRESE (COPAN, LUTECH) E UNA PICCOLA IMPRESA (HIANTIS). LE COMPETENZE INTEGRATE GARANTISCONO LA POTENZIALITà DI SVILUPPO E VALIDAZIONE CLINICA DI DISPOSITIVI MEDICI (IVD) E PROCESSI DIAGNOSTICI, RAPIDAMENTE IMPLEMENTABILI NELLA PRATICA CLINICA. OBIETTIVI DEL PROGETTO: SVILUPPO E OTTIMIZZAZIONE DI UN NUOVO METODO/PROCESSO PREANALITICO (APRILE-GIUGNO 2020), PER L ESTRAZIONE DELL RNA VIRALE DIRETTAMENTE DAL TAMPONE NASOFARINGEO, RENDENDO IL TEST RAPIDO, SEMPLICE, SICURO (INATTIVAZIONE VIRALE) ED ESEGUIBILE ANCHE SU TAMPONI TRASPORTATI A SECCO (ENTI COINVOLTI: (Italian)
0 references
THE PHASE 2 CONSORTIUM CONSISTS OF RESEARCH BODIES AND INDUSTRIAL PARTNERS, CHARACTERISED BY ONGOING COLLABORATIONS AND ESTABLISHED SECTOR-SPECIFIC EXPERTISE, ABLE TO ENSURE THE ACHIEVEMENT OF THE OBJECTIVES ON TIME. THE PARTNERSHIP CONSISTS OF 2 UNIVERSITIES (UNIVERSITÃ DI MILANO (UNIMI) AND UNIVERSITY OF MILAN-BICOCCA (UNIMIB)), 2 ASST (ASST MONZA, ASST PAPA GIOVANNI XXIII BERGAMO), 2 LARGE ENTERPRISES (COPAN, LUTECH) AND A SMALL ENTERPRISE (HIANTIS). INTEGRATED EXPERTISE ENSURES THE CLINICAL DEVELOPMENT AND VALIDATION POTENTIAL OF MEDICAL DEVICES (IVDS) AND DIAGNOSTIC PROCESSES, WHICH CAN BE QUICKLY IMPLEMENTED IN CLINICAL PRACTICE. PROJECT OBJECTIVES:Â DEVELOPMENT AND OPTIMISATION OF A NEW PRE-ANALYTICAL METHOD/PROCESS (APRIL-JUNE 2020), FOR THE EXTRACTION OF VIRAL RNA DIRECTLY FROM THE NASOPHARYNGEAL BUFFER, MAKING THE TEST QUICK, SIMPLE, SAFE (VIRAL INACTIVATION) AND EXECUTABLE ALSO ON DRY-CARRIED SWABS (ENTITIES INVOLVED: (English)
1 February 2022
0 references
MILANO
0 references
BERGAMO
0 references
BRESCIA
0 references
MONZA
0 references